The Lift Line

“For a family facing a cancer diagnosis, a percentage in a press release means little; the figure that matters is the bill at the end of the month.” (Y K Gupta, The Indian Express, 29 October 2026)

Why This Editorial Matters for Your Exam

In the news: The National Pharmaceutical Pricing Authority (NPPA) released a list of 543 brands of anti-cancer medicines with revised maximum retail prices (MRPs) on 28 October 2026. The new prices will take effect from 9 November 2026. In The Indian Express on 29 October, Y K Gupta asks the question the list cannot answer: will patients’ bills come down?

The writer is, in the paper’s words, “President, AIIMS Kalyani and former head, Department of Pharmacology, and dean, AIIMS, New Delhi”. For the decision itself, see our report on the trade margin cap, the roundup item on the order that notified it, the roundup item on the Supreme Court’s question about drug price regulation and The Hindu’s editorial on hospital drug pricing.

UPSC relevance:

  • GS Paper 2: health; access to affordable medicines; regulatory bodies and their powers.
  • GS Paper 3: the pharmaceutical industry; price regulation and markets; the Essential Commodities Act, 1955.
  • Prelims: NPPA and the Department of Pharmaceuticals; the Drugs (Prices Control) Order, 2013 and its Paragraphs 19 and 20; scheduled and non-scheduled drugs; the National List of Essential Medicines; trade margin; the Pharma Sahi Daam app.
  • Essay and Interview: affordability against innovation; out-of-pocket health spending.

The Crux in 60 Words

India has capped the trade margin on non-scheduled cancer drugs, and the first revised MRPs take effect in November. Gupta welcomes the logic but sets a harder test: the cap leaves the maker’s price alone, and hospitals can recover lost revenue elsewhere. Only tracking actual bills, supply and access will show whether patients gain.

Key Arguments at a Glance

A cap on trade margins lowers the printed MRP, but the reform should be judged by whether patients’ total bills fall, supply holds and innovation is still rewarded.

Supporting
  • The cap works on the distribution chain, not the maker: the MRP is re-derived from the manufacturer’s own price to stockist, so, the writer argues, the manufacturer’s earnings stay the same.
  • Patented immunotherapy drugs such as pembrolizumab, nivolumab and durvalumab are covered, where mark-ups multiply over many treatment cycles.
  • The 2019 pilot on 42 drugs cut MRPs of 526 brands by up to 90 per cent, but it did not measure availability or what patients finally paid.
  • Hospitals that earn on retail mark-ups may recover lost revenue through consultations, diagnostics, consumables or package rates.
Counter

The order already carries safeguards the column does not dwell on: production levels must be maintained, hospitals supplied directly are treated as the stockist, revised prices must be displayed, and overcharging is recoverable with interest; small manufacturers, for their part, fear for jobs and supply in remote areas.

Way Forward

The writer proposes a monitoring framework run by NPPA with healthcare institutions that tracks actual bills, availability, hospital billing and access, with itemised bills, periodic audits, clear rules for old stock and a post-implementation study of out-of-pocket spending.

Background and Context

The road to the new prices

Date Step
February 2019 NPPA rationalises trade margins on 42 non-scheduled anti-cancer drugs; MRPs of 526 brands fall by up to 90%
8 October 2026 NPPA’s Authority, at its 283rd meeting, takes up the cap for anti-cancer drugs
17 October 2026 Order S.O. 5690(E) invokes Paragraph 19 of the DPCO for 137 drugs
23 October 2026 NPPA publishes Frequently Asked Questions on the cap
28 October 2026 First list of revised MRPs, from data companies filed up to 27 October
9 November 2026 Revised prices scheduled to take effect

What the order does

The order rests on Paragraph 19: NPPA, “being satisfied that extraordinary circumstances exist and that intervention is necessary in public interest”, applied it to 137 non-scheduled anti-cancer drugs listed in its Table B, from Abemaciclib to Zolbetuximab. An Expert Committee constituted by the Ministry of Health and Family Welfare under the Directorate General of Health Services recommended the list, which “will be updated periodically”.

The order “puts a cap on trade margin of 30% and directs manufacturers to fix their Maximum Retail Price (MRP) based on price at first point of sale of product”, that is, the price to stockist or distributor (PTS/PTD) for March 2026. The formula is:

MRP = PTS/PTD x {1 + (TM / (100 - TM))} + applicable GST, where the trade margin (TM) may not exceed 30.

The order’s own example: a drug with a current MRP of 300 plus GST and a PTS of 70 may now carry an MRP of at most 70 x {1 + (30/70)} = 100 plus GST. The capped margin equals, in the Authority’s minutes, “a mark-up of 42.86% on the Price to Stockist/Price to Distributor”.

Other conditions in the order:

  • Reporting: manufacturers report revised prices within seven days of publication in the Gazette. Silence “shall be construed as non-reduction of MRP and shall result in initiating action for recovery of overcharged amount”.
  • Enforcement: State Drug Controllers monitor compliance, and overcharged amounts are recoverable along with interest.
  • Patented drugs: included. The Authority noted that “as per DPCO 2013, there is no restriction on the price fixation of the patented drugs except if exemption has been approved under Paragraph 32.”

Why non-scheduled drugs needed attention

Scheduled drugs already have ceiling prices; NPPA’s order counts 63 anti-cancer drugs on the NLEM under price control. Non-scheduled drugs are watched only for the annual increase in MRP. NPPA’s analysis, reported by PIB when the cap was approved, found an “average price mark-up of approximately 170%, reaching 700% or more in some cases”. The order also notes that “Differences have also been observed between prices charged through retail and hospital, including varying discounts on MRP.”

What the 28 October list shows

PIB’s release says the list “reflects the information submitted by companies” up to 27 October and “will be updated as and when manufacturers submit their revised prices of non-scheduled anti-cancer drugs”. NPPA has since posted a list based on data received up to 30 October, so 543 is a starting count, not a final one.

PIB’s sample table gives the scale of individual cuts (Rs, old MRP to revised MRP):

  • Anastrozole 1 mg, ANARZOLE, 10 tablets (RPG Life Sciences): 695.76 to 73.00
  • Bevacizumab 100 mg/4 ml, BEVACIZAB, 4 ml vial (Abbott): 21,767.70 to 5,930.13
  • Denosumab 60 mg, Debrumab, 1 ml pre-filled syringe (RPG): 22,031.25 to 5,941.00

When the order was notified, PIB said the cap “is expected to bring down the MRP of the identified non-scheduled anti-cancer drugs by up to 70%, depending on their existing price structures”. That is an expectation for the group; some sample rows fall further, others less.

The Analysis

The writer’s argument

Gupta opens with a principle: “A medicine’s price is shaped not by science but by how it travels from manufacturer to patient.” The column then sets the yardstick: “The reform should be judged by its consequences for patients, manufacturers, hospitals and innovation.”

On innovation, the column answers the industry’s worry directly: “trimming distribution margins does not touch the manufacturer’s realisation”. The column’s illustration is a hypothetical drug sold to a stockist for Rs 10,000 with an MRP of Rs 50,000, where the Rs 40,000 gap covers intermediary margins, distribution costs and taxes. “TMR recalculates the permissible MRP; the manufacturer’s earnings remain unchanged.” The formula supports the logic, since it starts from the manufacturer’s own March 2026 price to stockist; the claim about earnings is Gupta’s inference, not a line in the order.

On immunotherapy, the column notes that “Pembrolizumab, nivolumab and durvalumab are patented biologics whose prices the Drugs Prices Control Order does not normally regulate, yet the NPPA has included them.” All three are in Table B. Because treatment runs over many cycles, even modest mark-ups multiply. The column’s test: “TMR narrows it, but the real test is how much it improves affordability for patients.”

Four stakeholders, four tests

Stakeholder Gupta’s concern What the order already says
Manufacturers The 2019 pilot “does not show the effect on availability or actual patient bills”; “Supply chains must be monitored for stock-outs, particularly of low-cost older drugs.” Small manufacturers, the column reports, fear for jobs and availability in remote areas “The manufacturers of the formulations are required to maintain the present production levels”; a cut needs NPPA’s prior permission
Chemists “The key challenge is existing stock carrying older, higher MRPs”: relabelling and inventory need clear guidelines and a transition framework Manufacturers must file revised prices within seven days; NPPA has issued FAQs
Hospitals “The larger concern is whether hospitals recoup lost revenue through higher charges for consultations, diagnostics, consumables, procedures or bundled packages.” Hospitals supplied directly are treated as the stockist and must display revised prices; overcharging is recoverable with interest
Patients The bill at the end of the month, not the percentage in a press release Prices can be checked on the Pharma Sahi Daam app and NPPA’s website

On hospitals, Gupta warns against reading share prices as proof of harm: “TMR should be judged not by short-term share-price movements, but by whether it delivers measurable savings to patients without compromising the quality and affordability of cancer care.”

Where the column is strong, and where it stops

  • Strong: it moves the test from the MRP to the bill. A cancer patient pays for a course of treatment, and the order disciplines the price of the medicine, not of a consultation, a scan or a package.
  • It underplays the safeguards already written. The production, hospital-as-stockist, display and recovery rules answer part of its worry.
  • Its reading of patented drugs differs from the regulator’s. The column says the DPCO “does not normally regulate” patented biologics; the Authority’s own reading is that the DPCO places “no restriction on the price fixation of the patented drugs” unless a Paragraph 32 exemption applies.
  • Its proposal is a proposal. No monitoring framework of the kind it describes has been announced.

Way forward

  1. Measure the bill, not the label. “Transparent, itemised bills and periodic audits can show whether savings reach patients or are diluted elsewhere.”
  2. Build the evidence. NPPA, the writer argues, “should establish a monitoring framework that tracks actual patient bills, medicine availability, hospital billing patterns and treatment access”.
  3. Smooth the transition. Clear rules on old stock, relabelling and reconciliation, so that chemists can comply without undue burden.
  4. Watch supply. Track stock-outs, especially of cheap older drugs, and use the order’s production clause.
  5. Then extend, on evidence. The chemists’ body, the column reports, has urged a similar, evidence-based approach for other high-cost essential medicines.

The column’s closing line sets the bar: “If savings reach patients, supply holds, and innovation is rewarded, TMR will become a template for fairer pricing.”

Data and Institutions Vault

Prelims-grade facts:

The revision:

  • NPPA list of 28 October 2026: revised MRPs for 543 brands of anti-cancer medicines, from company data up to 27 October
  • Revised prices take effect from 9 November 2026; the list is updated as manufacturers file

The order:

  • S.O. 5690(E), dated 17 October 2026; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
  • Invokes Paragraph 19 of the DPCO, 2013 (extraordinary circumstances, public interest) for 137 non-scheduled anti-cancer drugs (Table B)
  • Trade margin capped at 30% of MRP, excluding GST; equal to a 42.86% mark-up on the price to stockist
  • Base price: the manufacturer’s price to stockist or distributor for March 2026
  • Patented drugs included; manufacturers file revised prices within 7 days; production levels must be maintained
  • Hospitals supplied directly count as the stockist; State Drug Controllers monitor; overcharge recoverable with interest

The evidence:

  • NPPA found average mark-ups of about 170%, up to 700% or more in some cases
  • February 2019: 30% cap on 42 anti-cancer drugs; MRPs of 526 brands cut by up to 90%; reported savings Rs 984 crore a year

Institutions:

  • NPPA: set up by Government Resolution of 29 August 1997; attached office of the Department of Pharmaceuticals
  • DPCO, 2013: issued under section 3 of the Essential Commodities Act, 1955
  • NPPA’s powers delegated by S.O. 1349(E) of 30 May 2013, under sections 3 and 5 of that Act
  • NLEM 2022: 384 drugs in 27 therapeutic categories (Health Ministry, September 2022; NPPA’s October 2026 order counts 388)
  • Pharma Sahi Daam app: consumers check revised drug prices

⚠️ Watch the trap:

  • The cap is on the trade margin, not a ceiling price; ceiling prices apply to scheduled (NLEM) drugs
  • “Up to 70%” is PIB’s expectation, not a measured fall
  • Paragraph 19 is the emergency power; Paragraph 20 limits annual MRP rises of non-scheduled drugs
  • The new MRPs apply from the effective date, not from the date the list was released

The Debate

The case for the margin cap The case for caution
Mark-ups averaging about 170% sit in the distribution chain, not in research or manufacture A lower MRP may not mean a lower bill if hospitals raise other charges
The manufacturer’s own price is the base, so the cap does not, in the writer’s view, cut its realisation Small manufacturers fear for jobs and supply in remote areas
The 2019 cap on 42 drugs cut MRPs of 526 brands by up to 90% That pilot reported savings on MRPs, not on availability or patient bills
Patented immunotherapy, used over many cycles, is covered Old stock at higher MRPs, and stock-outs of cheap older drugs, need managing

Balanced verdict: the cap attacks the right target, the margin added after the drug leaves the factory; but Gupta is right that its success has to be shown in bills, supply and access, and that evidence will come only if someone collects it.

How to Think About This

  1. Separate the tools. A ceiling price fixes what a drug may cost; a trade margin cap fixes how much the chain may add to the maker’s price. Each leaves something untouched.
  2. Follow the rupee to the patient. Ask where a cancer patient’s money goes: the drug, the hospital’s services, the tests. A cut in one line can be offset in another.
  3. Judge policy by outcomes. A price notification is an input; out-of-pocket spending, supply and access are the outcomes an answer should weigh.

Diagram-in-Words

Manufacturer’s price to stockist (March 2026) → + trade margin, within the cap → + GST = revised MRP → chemist or hospital → patient’s bill = medicine + consultations, diagnostics, consumables, procedures

The order reaches every link up to the MRP; the column’s worry is the last link, where the medicine is only one line on the bill.

✍️ Mains Answer Framework
Question

Distinguish between a ceiling price and trade margin rationalisation as tools of drug price control in India. Examine whether capping trade margins on anti-cancer medicines is likely to reduce patients' out-of-pocket expenditure. (250 words)

Introduction

India controls medicine prices under the Drugs (Prices Control) Order, 2013, issued under section 3 of the Essential Commodities Act, 1955. Scheduled drugs on the National List of Essential Medicines carry a ceiling price; non-scheduled drugs face only a limit on their annual MRP increase.
Trade margin rationalisation fills part of that gap, but a lower MRP is not yet a lower bill.

Body

A ceiling price caps what any seller may charge for a scheduled formulation. Trade margin rationalisation instead caps the gap between the manufacturer’s price to stockist and the MRP. By S.O. 5690(E) of 17 October 2026, the National Pharmaceutical Pricing Authority invoked Paragraph 19 of the DPCO, in extraordinary circumstances and in the public interest, for 137 non-scheduled anti-cancer drugs, capping the trade margin at 30 per cent of MRP excluding GST and directing makers to re-derive the MRP from their March 2026 price to stockist.
Patented drugs are included. The order also requires makers to maintain production, treats hospitals supplied directly as the stockist, and makes overcharging recoverable with interest.
Evidence points both ways. NPPA found an average mark-up of about 170 per cent in these medicines, and a 2019 cap on 42 drugs cut MRPs of 526 brands by up to 90 per cent.
But margin caps leave the manufacturer’s own price untouched, and much of a cancer patient’s cost lies outside the medicine: consultations, diagnostics, consumables and package rates, which a hospital can raise to recover lost revenue. Older stock printed at higher MRPs, and the risk that low-cost older drugs drop out of supply, can also delay or blunt the benefit.

Conclusion

The cap should lower what patients pay for the drug, but whether it lowers out-of-pocket spending depends on enforcement and on hospital billing. Itemised bills, audits of hospital charges, watch on stock-outs and a post-implementation study of patient spending would show whether the saving reaches the patient.

Interview Angle

"If a cap on trade margins leaves the manufacturer's own price untouched, how much can it really do for a cancer patient, and what would you watch to know whether it worked?"

Takeaway Box

  • The tool: trade margin rationalisation under Paragraph 19 of the DPCO, 2013, capping the margin at 30% of MRP for the listed non-scheduled cancer drugs.
  • The test: whether patients’ total bills fall, without stock-outs and without hospitals shifting costs to other charges.
  • For answers: distinguish ceiling price from margin cap, and cite the 2019 pilot’s 42 drugs and 526 brands.

Sources:

Cite this page: Cancer Drug Prices: Will the Margin Cap Cut Patients' Bills? — Ujiyari.com | Free UPSC & State PCS Editorial Analysis